Refine by
Health Care Products Articles & Analysis: Older
150 news found
With the New Year holiday just around the corner, CD Formulation is delighted to announce a limited-time promotional offer for industries seeking innovative solutions in pharmaceutical, cosmetic, and healthcare product development. From November 15, 2024, to January 5, 2025, clients can benefit from a substantial 5%-15% discount on all products and services provided by CD Formulation. This move ...
As the new academic year looms on the horizon, CD Formulation is ecstatic to announce a special Back to School Promotion 2024. Emphasizing its commitment to supporting educational and research institutions, the promotion offers up to 10% off on all their products and services. This timely initiative aims to facilitate ground-breaking research and innovation in pharmaceutical, cosmetic, and ...
The company is extending a generous discount on its range of innovative products and services, allowing customers to make the most of their holiday budget. ...
Currently, CD Formulation can provide mold development for different shapes and qualities of health care products including the following： l Tablets type health care products l Gummies health care products The benefits of CD Formulation's ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
ByBayer AG
As a result, demand for healthcare products has boomed over the past decade. Companies that manufacture health care products should better integrate their research and development of products using cutting-edge technologies. ...
This move is made because the company plans to further diversify its product lineup, in the hope to offer clients even more options. For many manufacturers either in the health care or pharmaceutical industry, choosing the right packaging can be a critical part of the product development process. ...
Asundexian is an investigational agent and has not been approved by any health authority for use in any country, for any indication. It is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention with the goal to reduce clot formation while leaving the body’s ability to respond to bleeding intact. ...
ByBayer AG
Thus, we welcome new research in extended treatment intervals that alleviate the situation for patients and the health care systems while achieving best visual acuity outcomes”, said Dr. ...
ByBayer AG
About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. ...
ByBayer AG
This is supported by the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS Phase III trial6 and the improved verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.7 The product is approved under the brand name Nubeqa™ in more than 80 countries around the world for ...
ByBayer AG
“Bayer is committed to improving health outcomes for people living with prostate cancerand that as many eligible patients as possible gain access to ...
ByBayer AG
Having long been providing pharmaceutical excipients, CD Formulation recently decided to upgrade its chemical database by adding more high-quality and cost-effective pharmaceutical excipients, cosmetic ingredients, and food ingredients. “Over the past decade, we have seen the rapid development of pharmaceutical, cosmetic, and food industries. As a trust-worthy biochemical company, we are ...
“We are committed to improving prostate cancer care across all stages of the disease and recognize that for patients and their families, quality of life is just as critical as prolonging survival and delaying disease progression. ...
ByBayer AG
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to ...
ByBayer AG
” Darolutamide plus ADT in combination with docetaxel was recently recommended for EU marketing authorization for the treatment of mHSPC by the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP), with a final decision expected in the coming months. ...
ByBayer AG
About Radiology at Bayer As a true life-science company with a heritage of over 100 years in Radiology, Bayer is committed to providing excellence, from innovative products to high-quality services, to support efficient and optimized patient care. ...
ByBayer AG
” “Blackford has built a strong reputation in the AI platform segment for radiology, with a wide portfolio of 3rd party products and a strong deployed base of hospitals, radiology groups and imaging centers,” said Ben Panter, Chief Executive Officer of Blackford. ...
ByBayer AG
Based on the positive results of both pivotal Phase III studies, FIDELIO-DKD and FIGARO-DKD, Kerendia™ was approved in March 2022 by the Japanese Ministry of Health, Labour, and Welfare (MHLW). Further regulatory approvals by other health authorities in multiple other countries have been granted or are currently pending following submissions for marketing ...
ByBayer AG
Aflibercept 8 mg will provide a 4-fold higher molar dose compared with the standard of care (aflibercept 2 mg) with an aim to increase Vascular Endothelial Growth Factor (VEGF) suppression time. ...
ByBayer AG